Xuelin (Steve) Wang
Lawyers
Filters
PegBio IPO
We advised PegBio on its IPO and HKEX listing
Visen Pharmaceutical HK$783.3 million IPO
The shares are listed on the HKEX
Ascentage Pharma $126.4 million IPO
The IPO is the first life sciences U.S. IPO of 2025 and the first life sciences company listed on the HKEX to complete a U.S. listing
BrainAurora Medical Technology HK$583 million IPO
We advised BrainAurora on its IPO and HKEX listing
Laekna HK$236 million placement of shares
We advised Laekna on the placement of new shares
Adagene $100 million at-the-market offering
We advised Adagene on the offering
H&H International CNY500 million bonds offering
The investment-grade notes are due 2027
HighTide Therapeutics HK$194.1 million IPO
We advised HighTide Therapeutics on its IPO and HKEX listing
WuXi XDC Cayman HK$3.68 billion IPO
The shares are listed on the HKEX
Genetron $126 million going-private transaction
We are separately advising Genetron and the special committee of its board on the transaction